Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr. Eric Leire joined Steve Darling from Proactive to share news the company has announced it has secured €4,026,525 in non-dilutive financial support from the Wallonia region, which will aid in the development of Genflow’s lead gene therapy, GF-1002. This therapy is being developed for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe liver disease.
The Wallonia region’s financial backing demonstrates the recognition of Genflow’s pioneering work in gene therapy. Dr. Leire explained that the support includes a non-reimbursable research grant covering 70% of Genflow’s research expenses and a recoverable advance funding 55% of the development costs, which will be repaid upon the commercialization of GF-1002.
This funding is expected to cover three years of development, and Genflow plans to secure the remaining funds required to fulfill its share of the project over this period. This marks a significant step forward in the fight against MASH, as the …